期刊
NEUROSCIENCE LETTERS
卷 494, 期 1, 页码 54-56出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2011.02.054
关键词
Brain-derived neurotrophic factor (BDNF); Lithium; Bipolar disorder; Mania; Neuroprotection; Neurotrophic
资金
- Espirita Hospital of Porto Alegre
- Stanley Medical Research Institute
- USA (SMRI)
- Associacao Beneficente Alzira Denise Hertzog da Silva (ABADHS)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
- Institut Nacional de Ciencia e Tecnologia em Excitoxicidade e Neuroprotecao (INCTen)
Several studies have suggested an important role for brain-derived neurotrophic factor (BDNF) in the pathophysiology and therapeutics of bipolar disorder (BPD). The mechanisms underlying the therapeutic effects of lithium in BPD seem to involve a direct regulation of neurotrophic cascades. However, no clinical study evaluated the specific effects of lithium on BDNF levels in subjects with BPD. This study aims to investigate the effects of lithium monotherapy on BDNF levels in acute mania. Ten subjects with bipolar I disorder in a manic episode were evaluated at baseline and after 28 days of lithium therapy. Changes in plasma BDNF levels and Young Mania Rating Scale (YMRS) scores were analyzed. A significant increase in plasma BDNF levels was observed after 28 days of therapy with lithium monotherapy (510.9 +/- 127.1 pg/mL) compared to pre-treatment (406.3 +/- 69.5 pg/mL) (p = 0.03). Although it was not found a significant association between BDNF levels and clinical improvement (YMRS), 87% of responders presented an increase in BDNF levels after treatment with lithium. These preliminary data showed lithium's direct effects on BDNF levels in bipolar mania, suggesting that short-term lithium treatment may activate neurotrophic cascades. Further studies with larger samples and longer period may confirm whether this biological effect is involved in the therapeutic efficacy of lithium in BPD. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据